Harpoon Therapeutics, Inc. (HARP) financial statements (2021 and earlier)

Company profile

Business Address 131 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:155121134148 
Cash and cash equivalents89575296 
Short-term investments59648243 
Other undisclosed cash, cash equivalents, and short-term investments7(0)09 
Other undisclosed current assets(4)23(7) 
Total current assets:151123137141 
Noncurrent Assets
Operating lease, right-of-use asset77  
Property, plant and equipment1112126 
Long-term investments and receivables7  9 
Long-term investments7  9 
Other noncurrent assets1101 
Other undisclosed noncurrent assets  711 
Total noncurrent assets:26192026 
TOTAL ASSETS:177142157167 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities101297 
Accounts payable3453 
Accrued liabilities7854 
Deferred revenue114  
Debt11   
Contract with customer, liability44 
Other undisclosed current liabilities  11 
Total current liabilities:23171512 
Noncurrent Liabilities
Long-term debt and lease obligation1414   
Operating lease, liability1414  
Liabilities, other than long-term debt46467 
Deferred revenue464  
Contract with customer, liability67 
Other undisclosed noncurrent liabilities  1415 
Total noncurrent liabilities:60182021 
Total liabilities:82353533 
Stockholders' equity
Stockholders' equity attributable to parent94107122134 
Common stock0000 
Additional paid in capital212211210210 
Accumulated other comprehensive income0000 
Accumulated deficit(118)(104)(88)(76) 
Total stockholders' equity:94107122134 
TOTAL LIABILITIES AND EQUITY:177142157167 

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
Gross profit:2111 
Operating expenses(17)(18)(14)(15) 
Operating loss:(15)(17)(13)(14) 
Nonoperating income1111 
Investment income, nonoperating1111 
Loss before gain (loss) on sale of properties:(14)(16)(12)(14) 
Other undisclosed net loss(0)  (0) 
Net loss available to common stockholders, diluted:(14)(16)(12)(14) 

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
Net loss:(14)(16)(12)(14) 
Other comprehensive income (loss) (0)00 
Other undisclosed comprehensive income0    
Comprehensive loss:(14)(16)(12)(14) 
Other undisclosed comprehensive loss, net of tax, attributable to parent(0)    
Comprehensive loss, net of tax, attributable to parent:(14)(16)(12)(14) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: